RCT | Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension.
8 Aug, 2022 | 11:30h | UTCBalloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Pulmonary vascular resistance reduction was more pronounced with balloon pulmonary angioplasty (BPA) than with riociguat, but treatment-related SAEs were more common with BPA
Read the RACE trial from Xavier Jaïs & colleagues https://t.co/h9r3Qe2mCb
— The Lancet Respiratory Medicine (@LancetRespirMed) August 2, 2022